Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (351-360 of 607) with videos related to

Pageof 61
Sort By:
Cells|April 26, 2024
Exploring Anti-Fibrotic Effects of Adipose-Derived Stem Cells: Transcriptome Analysis upon Fibrotic, Inflammatory, and Hypoxic ConditioningMarvin L Frommer, Benjamin J Langridge, Alexandra Beedie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 31, 2025
Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic SclerosisStefano Di Donato, Rebecca Ross, Ranjitha Karanth, et al.
Heart (British Cardiac Society)|December 13, 2005
Systemic sclerosis associated pulmonary hypertension: improved survival in the current eraM H Williams, C Das, C E Handler, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|July 15, 2024
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosisElizabeth R Volkmann, Christopher P Denton, Martin Kolb, et al.
American Journal of Respiratory and Critical Care Medicine|December 1, 2021
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled TrialDinesh Khanna, Celia J F Lin, Daniel E Furst, et al.
Current Medical Research and Opinion|July 23, 2019
Progressive fibrosing interstitial lung diseases: current practice in diagnosis and managementMarlies Wijsenbeek, Michael Kreuter, Amy Olson, et al.
Arthritis and Rheumatism|December 1, 2007
Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblastsXu Shi-wen, Laura Kennedy, Elisabetta A Renzoni, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 7, 2018
Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2Justin Gillespie, Rebecca L Ross, Clarissa Corinaldesi, et al.
Cells|February 15, 2022
Induction of Pro-Fibrotic CLIC4 in Dermal Fibroblasts by TGF-β/Wnt3a Is Mediated by GLI2 UpregulationChristopher W Wasson, Begoña Caballero-Ruiz, Justin Gillespie, et al.
Annals of the Rheumatic Diseases|September 10, 2013
Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitorsBritta Maurer, Alfiya Distler, Clara Dees, et al.
Pageof 61

Showing results (351-360 of 607) with videos related to

Sort By:
Pageof 61
Cells|April 26, 2024
Exploring Anti-Fibrotic Effects of Adipose-Derived Stem Cells: Transcriptome Analysis upon Fibrotic, Inflammatory, and Hypoxic ConditioningMarvin L Frommer, Benjamin J Langridge, Alexandra Beedie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 31, 2025
Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic SclerosisStefano Di Donato, Rebecca Ross, Ranjitha Karanth, et al.
Heart (British Cardiac Society)|December 13, 2005
Systemic sclerosis associated pulmonary hypertension: improved survival in the current eraM H Williams, C Das, C E Handler, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|July 15, 2024
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosisElizabeth R Volkmann, Christopher P Denton, Martin Kolb, et al.
American Journal of Respiratory and Critical Care Medicine|December 1, 2021
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled TrialDinesh Khanna, Celia J F Lin, Daniel E Furst, et al.
Current Medical Research and Opinion|July 23, 2019
Progressive fibrosing interstitial lung diseases: current practice in diagnosis and managementMarlies Wijsenbeek, Michael Kreuter, Amy Olson, et al.
Arthritis and Rheumatism|December 1, 2007
Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblastsXu Shi-wen, Laura Kennedy, Elisabetta A Renzoni, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 7, 2018
Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2Justin Gillespie, Rebecca L Ross, Clarissa Corinaldesi, et al.
Cells|February 15, 2022
Induction of Pro-Fibrotic CLIC4 in Dermal Fibroblasts by TGF-β/Wnt3a Is Mediated by GLI2 UpregulationChristopher W Wasson, Begoña Caballero-Ruiz, Justin Gillespie, et al.
Annals of the Rheumatic Diseases|September 10, 2013
Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitorsBritta Maurer, Alfiya Distler, Clara Dees, et al.
Pageof 61